Search / 60 results found

from
to
  • Updated

DALLAS and SAN ANTONIO, March 5, 2021 /PRNewswire-PRWeb/ -- Everest Rehabilitation Hospitals today announced plans to construct its 8th identical, modern, 36-bed, inpatient physical rehabilitation hospital in South San Antonio, Texas. The single story, $24 million dollar hospital investment is centered conveniently on 8.1 acres between Interstates 35 and 37 on S. E. Military Parkway. The construction is planned for completion in twelve months.

  • Updated

WORCESTER, Mass., March 5, 2021 /PRNewswire/ -- The 800 nurses of St. Vincent Hospital in Worcester are prepared to conduct an open-ended strike beginning on Monday, March 8 at 6 a.m., with a Pre-Strike Community Rally planned for Sunday, March 7 at 4:30 p.m.  The planning for the strike intensified following failed negotiations on Wednesday, when Dallas-based Tenet Healthcare walked away from the table, having once again refused to address the nurses' longstanding call for desperately needed staffing improvements to ensure safer patient care.

  • Updated

FT. WORTH, Texas, March 4, 2021 /PRNewswire/ -- Today, FDS, a pharmacy software solutions company, and Amplicare, its sister company since their merger in Sept. 2020, announced a new brand; FDS Amplicare. The new brand embodies the collective strength the organization offers pharmacies and patients through its suite of software solutions.

  • Updated

FORT WORTH, Texas, March 4, 2021 /PRNewswire/ -- EHR Data announces the launch of its advocacy movement, EHR Data Wavemakers. The purpose of this movement is to encourage, educate, and support individuals on the journey to patient empowerment. EHR Data firmly believes people will lead better, healthier lives if they have unfettered access and control of their personal health information.

  • Updated

HOUSTON, March 4, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021. 

  • Updated

HOUSTON, March 4, 2021 /PRNewswire/ -- DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced the treatment of the first patient in a Phase 1 dose-escalation and dose-expansion study of DNX-2440, an OX40 ligand encoding oncolytic adenovirus, in patients with resectable liver metastasis. Expression of OX40 ligand on the surface of tumor cells is expected to enhance anti-tumor immune responses by providing costimulatory signals to T cells within the tumor microenvironment.

  • Updated

DALLAS and KELLER, Texas and OKLAHOMA CITY, March 3, 2021 /PRNewswire-PRWeb/ -- Everest Rehabilitation Hospitals, LLC is pleased to announce the sale of two of their operating rehabilitation hospitals (Oklahoma City, OK and Keller, TX). The hospital sales were made to Kindred / Texas Health Resources in Keller, TX and Kindred / Mercy Hospitals in Oklahoma City, OK.

  • Updated

AUSTIN, Texas, March 3, 2021 /PRNewswire/ -- Lena's Journey, a new Virtual Reality (VR) mini-series, is the cornerstone of Western State Hospital's (WSH) newly revamped 2-week employee training program. The five-part series, produced by Chocolate Milk & Donuts, was created to immerse employees into the lives of those living with severe mental illness. The goal is to help staff better empathize with patients. The training program is the first of its kind to leverage 360 video technology and storytelling in this way.

  • Updated

TYLER, Texas, March 3, 2021 /PRNewswire/ -- There are many reasons patients may find themselves in a chiropractor's office: A pinched nerve in the back, sciatica, neck and shoulder pain and headaches. These are just a few of the causes that everyday people seek out relief.

  • Updated

DALLAS, March 3, 2021 /PRNewswire/ -- Dialectic Therapeutics, Inc. (Dialectic®), a Texas-based biotechnology company focused on creating innovative new technologies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has concluded that Dialectic may proceed with its clinical investigation for its lead product candidate, DT2216, a unique compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD™) technology. In pre-clinical studies supported through a Seed Award from the Cancer Prevention & Research Institute of Texas (CPRIT), DT2216 selectively induces cancer cells to degrade B-cell lymphoma extra-large, or BCL-XL, stimulating the cells to commit suicide or become more susceptible to chemotherapy.